OBJECTIVE-In the pancreatic ␤-cell, ATP-sensitive K ϩ (K ATP ) channels couple metabolism with excitability and consist of Kir6.2 and SUR1 subunits encoded by KCNJ11 and ABCC8, respectively. Sulfonylureas, which inhibit the K ATP channel, are used to treat type 2 diabetes. Rare activating mutations cause neonatal diabetes, whereas the common variants, E23K in KCNJ11 and S1369A in ABCC8, are in strong linkage disequilibrium, constituting a haplotype that predisposes to type 2 diabetes. To date it has not been possible to establish which of these represents the etiological variant, and functional studies are inconsistent. Furthermore, there have been no studies of the S1369A variant or the combined effect of the two on K ATP channel function.
R ecent large-scale human genetic studies have made dramatic progress in identifying type 2 diabetes susceptibility genes, increasing the list from three genes (PPARG, KCNJ11, and TCF7L2) to nearly 20 genes in the last 2 years (1). Despite this rapid progress, what the precise causal variant is and how the variant increases susceptibility to type 2 diabetes is still unknown in the majority of cases. Even the widely accepted type 2 diabetes susceptibility gene KCNJ11 has not yet had the mutational mechanisms fully elucidated.
In pancreatic ␤-cells and the central nervous system, ATP-sensitive K ϩ (K ATP ) channels are composed of the Kir6.2 and SUR1 subunits encoded by the KCNJ11 and ABCC8 genes, respectively. K ATP channels act as key transducers of metabolic signals to excitability in many cell types including the regulation of insulin secretion (2) , and the K ATP channel is the target for commonly used antidiabetic sulfonylurea drugs (3) . The importance of the K ATP channel in diabetes is highlighted by the fact that rare heterozygous activating mutations in KCNJ11 or ABCC8 cause diabetes with varying clinical severities (4 -6) .
One of the first reproducibly associated type 2 diabetes susceptibility signals identified was the common E23K (rs5219) variant of KCNJ11 (7, 8) . Functional studies were subsequently performed, but the results were inconsistent (9 -11) . Moreover, fine mapping in the region demonstrated the difficulty in identifying the causal variant when a second nonsynonymous (S1369A; rs757110) variant in the neighboring ABCC8 gene was shown to be in complete linkage disequilibrium with the E23K KCNJ11 variant (12) . The implications of this were that 1) it was not possible from the genetic evidence to say which variant is actually the etiological variant and 2) individuals who carried the K risk allele of the E23K variant also carried the A risk allele of the S1369A variant. Consequently, functional studies to investigate the mutational mechanism need to include both variants. using fluorescent optics in combination with coexpression of a green fluorescent protein plasmid (Life Technologies, Gaithersburg, MD). Macroscopic K ATP channel recordings were then performed 48 -72 h after transfection. The inside-out patch-clamp technique was used to measure macroscopic K ATP channel currents in transfected tsA201 cells as described in detail previously (13) . Experimental compounds. MgATP and MgADP (Sigma, Oakville, Ontario) were prepared as 10 mmol/l stocks in ddH 2 O immediately prior to use. Glibenclamide, gliclazide, and repaglinide (Sigma, Oakville, Ontario) were prepared as 10 mmol/l stocks in DMSO and stored at Ϫ20°C. DMSO concentration was maintained at 0.1% in all experimental solutions. Statistical analysis. Macroscopic K ATP channel currents were normalized and expressed as changes in current relative to control (i.e., normalized K ATP channel current ϭ I test /I control ). Single-channel analysis was performed using pClamp v. 10.0 software (Axon Instruments). Statistical significance was assessed using the unpaired Student's t test or one-way ANOVA with a Bonnferoni post hoc test. P Ͻ 0.05 was considered statistically significant. Data are expressed as means Ϯ SE.
RESULTS
Residue S1369 is proximal to the second nucleotidebinding domain in SUR1, which forms part of the MgATPand MgADP-sensing region in SUR1 that is a key regulator of K ATP channel activity and, hence, insulin secretion (3, 14) . However, the direct effects of the K23/A1369 variant on human K ATP channel nucleotide sensitivities have not been investigated. Therefore, to gain insights into the nucleotide regulation of K23/A1369 variant K ATP channel activity, the MgATP and MgADP sensitivities of recombinant human K ATP channels containing either the K23/A1369 or the E23/S1369 variants were compared. Our results indicate that the K23/A1369 variant decreases the MgATP sensitivity of the K ATP channel (half-maximal inhibitory concentration [IC 50 ] ϭ 8.0 Ϯ 0.8 vs. 2.5 Ϯ 0.2 mol/l for the E23/S1369 variant, P Ͻ 0.05; Fig. 1A and B). Extrapolation of the MgATP concentration-inhibition curve to physiological millimolar intracellular MgATP levels (1-5 mmol/l) predicted that the shift in IC 50 may result in the K23/A1369 variant remaining slightly more active compared with the E23/S1369 variant (Fig. 1B, inset) . Subsequent singlechannel experiments confirmed this prediction with the open probability of the K23/A1369 variant being significantly greater than the E23/S1369 variant at 1 mmol/l MgATP but not at 0 mmol/l MgATP ( Fig. 1C-F ). To determine whether one or both of the K23 or A1369 variants account for the reduced MgATP sensitivity, MgATP concentration-inhibition curves were constructed from quasi-heterologous K ATP channels expressing either E23/A1369 or K23/S1369. These results indicate that it is the ABCC8 A1369 variant, not the KCNJ11 K23 variant, that confers the reduced MgATP sensitivity to the K ATP channel complex (IC 50 ϭ 8.2 Ϯ 1.6 vs. 3.2 Ϯ 0.3 mol/l for E23/A1369 vs. K23/S1369, respectively; Fig. 1G ).
The intracellular ATP-to-ADP ratio is a major determinant of K ATP channel activity because MgADP antagonizes the inhibitory effects of ATP, and rare monogenic mutations in ABCC8 that reduce MgADP antagonism decrease channel activity and cause hyperinsulinism (14) . Accordingly, the stimulatory effects of varying concentrations of MgADP were tested in the presence of 0.1 mmol/l MgATP. However, no significant differences were observed between the E23/S1369 and K23/A1369 K ATP channel variants ( Fig. 2A and B) .
The K ATP channel is the molecular target for sulfonylurea and glinide drugs that are commonly used to stimulate insulin secretion in type 2 diabetes. Interestingly, recent clinical data suggest that diabetic patients who are homozygous for the A1369 risk allele (A/A) are more responsive to gliclazide therapy (15) . However, it is unknown whether this is due to a direct effect on the K ATP channel because the inhibitory profile of gliclazide and other drugs on the K23/A1369 variant K ATP channel has not been determined.
Sulfonylurea and glinide drugs can be grouped according to their binding to the A, B, or AB sites in the K ATP channel complex (3, 16, 17) . The A site is located close to SUR1 transmembrane segments 14 -16, and the S1237Y mutation in this region (Fig. 3A) abolishes A-site drug inhibition (18) . Two regions of the K ATP channel contribute to the B site: the intracellular loop between SUR1 transmembrane segments 5 and 6 and the NH 2 -terminus of Kir6.2 (16) (Fig. 3A) . Figure 3B shows the structures of the glinide repaglinide (B site) and the sulfonylureas glibenclamide (AB site) and gliclazide (A site). The SUR1 residue S1369 is in close proximity to the A site (Fig. 3A) . Therefore, the A1369 variant may contribute to altered K ATP channel sensitivity to A-site drugs such as gliclazide. Gliclazide (300 nmol/l) inhibited the K23/A1369 variant to a greater extent than the E23/S1369 variant ( Fig. 3C and  D) . Construction of gliclazide concentration-inhibition curves revealed that the K23/A1369 variant was 3.5-fold more sensitive to gliclazide inhibition than the E23/S1369 variant (IC 50 52.7 Ϯ 11.1 vs. 188.7 Ϯ 32.6 nmol/l, respectively; Fig. 3E ). Because the K23/A1369 K ATP channel variant may also alter the potency of other drug classes, the effects of glibenclamide (AB site) and repaglinide (B site) were tested. In direct contrast to the observed effects of gliclazide, no significant differences in either glibenclamide (3 nmol/l) or repaglinide (10 nmol/l) inhibition were found between the K23/A1369 and E23/S1369 variant K ATP channels (Fig. 3F) . It is possible that gliclazide inhibition may be affected by intracellular MgADP. In the presence of 0.1 mmol/l MgATP and 0.1 mmol/l MgADP, 300 nmol/l gliclazide still elicited a significantly greater inhibition of the K23/A1369 K ATP channel variant than the E23/S1369 variant (Fig. 4A-C) .
The data presented indicate that the K23/A1369 variant K ATP channel is more sensitive to inhibition by gliclazide but not glibenclamide or repaglinide. However, the relative individual contributions of the ABCC8 A1369 or KCNJ11 K23 variants to gliclazide sensitivity have not been determined. Therefore, gliclazide inhibition was measured in quasi-heterologous K ATP channels containing either the E23/A1369 or K23/S1369 variant combinations. E23/A1369 K ATP channels displayed a significantly greater gliclazide inhibition than K23/S1369 K ATP channels, which was similar in magnitude to that observed in the increased diabetes risk for the K23/A1369 variant K ATP channel (Fig.  4D-F) . Results from these experiments indicate that the enhanced gliclazide sensitivity in the K23/A1369 K ATP 
DISCUSSION
Previous studies have investigated the properties of K ATP channels containing the KCNJ11 K23 variant (9 -11), although Ͼ95% of people with two copies of K23 are also homozygous for A1369 (12) . Therefore, this study is the first to document the properties and pharmacology of the most commonly found K ATP channel variant that contains both K23 and A1369 risk alleles. Our study reveals novel differences in both the MgATP and sulfonylurea sensitivity of this variant K ATP channel. With respect to MgATP sensitivity, the moderate rightward shift in IC 50 for MgATP inhibition seen in the K23/A1369 variant results in increased basal K ATP channel activity at physiological MgATP levels. In direct contrast to the rare monogenic K ATP channel mutations that cause neonatal diabetes and drastically decreased MgATP inhibition, a modest increase in K23/A1369 variant K ATP channel activity may predispose to type 2 diabetes in combination with other factors. Indeed, we have previously shown that the K23 variant increases the sensitivity of the K ATP channel to activation by intracellular acyl CoAs (11, 13) . K ATP channels encoded by the KCNJ11 and ABCC8 genes are also expressed in pancreatic ␣-cells and hypothalamic neurons that centrally regulate glucose/ energy homeostasis (19) . Therefore, it is plausible that subtle increases in the activity of K23/A1369 variant K ATP channels may alter glucagon secretion and centrally mediated glucose homeostasis, further contributing to the development of type 2 diabetes.
The molecular mechanism for the reduced ATP inhibition observed in K ATP channels expressing the K23/A1369 variant proteins is of importance. Free ATP inhibits K ATP channel activity via binding to the Kir6.2 subunit, whereas, paradoxically, MgATP can activate the channel via intrinsic MgATPase activity of the nucleotide-binding folds in SUR1, resulting in production of MgADP that may stimulate channel activity (2) . In direct contrast to a previous study on the KCNJ11 K23 variant (20) , our results indicate that the stimulatory effects of MgADP are unaltered in the K23/A1369 variant K ATP channel, suggesting that the molecular mechanism for decreased ATP inhibition does not involve altered MgADP sensitivity per se. Our results also show that the observed decrease in ATP inhibition in the K23/A1369 variant K ATP channel results from a direct effect of the ABCC8 A1369 risk allele reducing ATP inhibition (9) , perhaps via mild increases in the intrinsic K ATP channel MgATPase activity. Indeed, several rare heterozygous mutations in ABCC8 that cause neonatal diabetes (R1380L and R1380C) act by increasing MgATPase activity (21) . Interestingly, the location of the ABCC8 S1369 residue is in close proximity to the MgATPase catalytic site and residue R1380 in the SUR1 nucleotidebinding fold 2 (22) .
Sulfonylurea and glinide drugs that inhibit K ATP channels are in extensive clinical use to stimulate insulin secretion in patients with type 2 diabetes (3). Glibenclamide is an AB-site ligand and is the most widely used sulfonylurea, whereas gliclazide is an A-site ligand selectively inhibiting K ATP channels containing the SUR1 isoform, potentially mitigating any cardiotoxicity that has been associated with glibenclamide monotherapy (23, 24) . Our results indicate that the K23/A1369 variant K ATP channel is 3.5-fold more sensitive to gliclazide. These findings are the first to directly demonstrate altered sulfonylurea sensitivities of the K23/A1369 variant K ATP channel and identify the ABCC8 A1369 risk allele as conferring this effect upon the K23/A1369 variant K ATP channel. These results provide a molecular mechanism for the increase in clinical efficacy of gliclazide in subjects with type 2 diabetes who are homozygous for the A1369 allele variant (15).
In conclusion, this study provides the first evidence that the ABCC8 S1369A variant alters the properties of the K ATP channel that may contribute to the increased risk for type 2 diabetes associated with the K23/A1369 risk haplotype. The increased gliclazide sensitivity observed in the K23/A1369 variant K ATP channel (afforded by the ABCC8 A1369 risk allele) encourages the study of sulfonylurea pharmacogenomics in larger cohorts and supports a rationale for tailoring pharmacotherapy in the ϳ20% of type 2 diabetic patients who carry two copies of these risk alleles. No potential conflicts of interest relevant to this article were reported.
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